Search | Clinical Trials Finder

Conditions: Muscular Atrophy, Spinal
Interventions: Placebo, Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Palo Alto, California • New York, New York

Conditions: Crohn's Disease, Ulcerative Colitis
Interventions: Zasocitinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Glen Burnie, Maryland • Tyler, Texas

Conditions: Bacterial Infections
Interventions: Clindamycin, trimethoprim-sulfamethoxazole; Drug
Lead sponsor: Michael Cohen-Wolkowiez; Other
Eligibility: 1 Month to 16 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: Little Rock, Arkansas • Chicago, Illinois • Ann Arbor, Michigan

Conditions: Healthy
Interventions: INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Muscular Atrophy, Spinal
Interventions: RO6885247, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Up to 55 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: Stanford, California • Orlando, Florida • Chicago, Illinois + 3 more

Conditions: Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
Interventions: QR-1123, Sham procedure; Drug · Other
Lead sponsor: ProQR Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 5
States / cities: Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more

Conditions: Advanced Cancers
Interventions: Temsirolimus, Metformin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 14 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anemia of Chronic Kidney Disease
Interventions: Vadadustat; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 4 Months to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Clostridoides Difficile Associated Disease
Interventions: C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 936 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 23
States / cities: Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more

Conditions: Advanced Solid Tumors
Interventions: TEV-56278, Pembrolizumab; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 11
States / cities: Los Angeles, California • Lake Mary, Florida • Chicago, Illinois + 7 more

Conditions: Cytokine Release Syndrome
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Clearwater, Florida • Chicago, Illinois • Chattanooga, Tennessee

Conditions: Colitis, Ulcerative
Interventions: placebo, MultiStem low dose, MultiStem high dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 37
States / cities: San Francisco, California • Lafayette, Colorado • Lakewood, Colorado + 24 more

Conditions: Coronary Disease
Interventions: RUC-4 Compound; Drug
Lead sponsor: CeleCor Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Steatohepatitis
Interventions: AZD7503; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Chandler, Arizona • Montclair, California • Hialeah, Florida + 5 more

Conditions: Peripheral T-cell Lymphoma
Interventions: Belinostat, CHOP; Drug
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 8
States / cities: New Haven, Connecticut • Athens, Georgia • Rochester, Minnesota + 5 more

Conditions: Non-Muscle Invasive Bladder Neoplasms
Interventions: Erdafitinib Intravesical Delivery System; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 25
States / cities: Birmingham, Alabama • Los Angeles, California • Lone Tree, Colorado + 22 more

Conditions: Influenza
Interventions: Text message reminder; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 18 Years
Enrollment: 228,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions: Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 60 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
Interventions: Fenretinide; Drug
Lead sponsor: SciTech Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 10
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more

Conditions: Healthy
Interventions: PF-06480605, Placebo; Drug
Lead sponsor: Telavant, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Degenerative Spine Disease
Interventions: FIBERGRAFT™ Aeridyan Matrix Bone Graft Substitute, Demineralized Bone Matrix; Device
Lead sponsor: DePuy Synthes Products, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 5
States / cities: Sacramento, California • Chicago, Illinois • Lexington, Kentucky + 2 more

Conditions: Melanoma
Interventions: Talimogene laherparepvec, Pembrolizumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 10
States / cities: Santa Barbara, California • Newark, Delaware • Orlando, Florida + 7 more

Conditions: Type 2 Diabetes
Interventions: CAT 1004, Placebo; Drug
Lead sponsor: Catabasis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Leukemia, Myeloid, Acute
Interventions: VCAR33; Biological
Lead sponsor: Vor Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 14
States / cities: La Jolla, California • Stanford, California • Miami, Florida + 11 more

Search by objective public record fields.

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Safety and Tolerability Study of IV ST266 in COVID-19 Subjects

A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis

A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH.

Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Influenza Reminder Text-Messaging

Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.

FIBERGRAFT Aeridyan Posterolateral Fusion Study

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

A Multiple Ascending Dose Study of CAT-1004 in Patients With Type 2 Diabetes

Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant